The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting

Autor:	Rami Kotb, Donna E. Reece, Hannah Cherniawsky, Richard Leblanc, Tony Reiman, Chritopher Venner, Eshetu G. Atenafu, Kevin W. Song, Arleigh MrCurdy, Julie Stakiw, Michael Sebag, Esther Masih-Khan, Martha L Louzada, Vishal Kukreti, Engin Gul, Muhammad Aslam, Darrell White, Victor H Jimenez-Zepeda
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Hematology medicine.disease Second line chemotherapy Internal medicine medicine business Multiple myeloma Lenalidomide medicine.drug
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 19:e250
ISSN:	2152-2650
DOI:	10.1016/j.clml.2019.09.414
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5444acf5c5a6f299c0376c35822f032a https://doi.org/10.1016/j.clml.2019.09.414 Zobrazit plný text záznamu Full Text from ScienceDirect